
LEO Pharma has closed its acquisition of dersimelagon from Tanabe Pharma after the FDA accepted the drug's NDA for filing and granted Priority Review, with a PDUFA date expected by the end of February 2027.
With the year coming to a close, we want to thank all of our contributors for the clinical images they submitted to Dermatology Times in 2018. From leg ulcers to dermatofibroma to scars, view our top picks in this slideshow.






